Non-peptide angiotensin II receptor antagonists: Chemical feature based pharmacophore identification

Journal of Medicinal Chemistry

Volumn 46, Issue 5, 2003, Pages 716-726

  Krovat, Eva M ^a   Langer, Thierry ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST;

ARTICLE; DRUG CONFORMATION; DRUG STRUCTURE; HYDROGEN BOND; HYDROPHOBICITY; IC 50; MOLECULAR MODEL; PHARMACOPHORE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ACRYLATES; ALGORITHMS; ANGIOTENSIN II; BIPHENYL COMPOUNDS; DATABASES, FACTUAL; IMIDAZOLES; LACTONES; LOSARTAN; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PYRIDINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; SULFONES; TETRAZOLES; THIOPHENES;

EID: 0037468539     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm021032v     Document Type: Article

References (53)

1. Sandow, N. Angiotensin Converting Enzyme (ACE) Inhibitors: Side Effects and Adverse Reactions. http://www.rxlist.com/aceinh.htm (accessed 2002).
2. Tabibiazar, R.; Jamali, A. H.; Rockson, S. G. Formulating Clinical Strategies for Angiotensin Antagonism: A Review of Preclinical and Clinical Studies. Am. J. Med. 2001, 110, 471-480.
3. Pitt, B.; Konstam, M. A. Overview of Angiotensin II-Receptor Antagonists. Am. J. Cardiol. 1998, 82, 47-49.
4. Boucard, A. A.; Wilkes, B. C.; Laporte, S. A.; Escher, E.; Guillemette, G.; Leduc, R. Photolabeling Identifies Position 172 of the Human AT1 Receptor as a Ligand Contact Point: Receptor-Bound Angiotensin II Adopts an Extended Structure. Biochemistry 2000, 39, 9662-9670.
5. Yoo, S.; Kim, S.; Lee, S.; Kim, N.; Lee, D. The Conformation and Activity Relationship of Benzofuran Type of Angiotensin II Receptor Antagonists. Bioorg. Med. Chem. 2000, 8, 2311-2316.
6. Kurup, A.; Gary, R.; Carini, D. J.; Hansch, C. Comparative QSAR: Angiotensin II Antagonists. Chem. Rev. 2001, 101, 2727-2750.
7. Pandya, T.; Pandey, S. K.; Tiwari, M.; Chaturvedi, S. C.; Saxena, A. K. 3-D-QSAR Studies of Triazolinone Based Balanced AT1/AT2 Receptor Antagonists. Bioorg. Med. Chem. 2001, 9, 291-300.
8. Underwood, D. J.; Strader, C. D.; Rivero, R.; Patchett, A. A.; Grenlee, W.; Prendergast, K. Structural model of antagonist and agonist binding to the angiotensin II, AT1 subtype, G protein coupled receptor. Chem. Biol. 1994, 1, 211-221.
9. Duncia, J. V.; Carini, D. J.; Chiu, A. T.; Johnson, A. L.; Price, W. A.; Wong, P. C.; Wexler, R. R.; Timmermans, P. B. M. W. The Discovery of DuP 753, a Potent, Orally Active Nonpeptide Angiotenisin II Receptor Antagonist. Med. Res. Rev. 1992, 12, 149-191.
10. Kiyama, R.; Honma, T.; Hayashi, K.; Ogawa, M.; Hara, M.; Fujimoto, M.; Fujishita, T. Novel Angiotensin II Receptor Antagonists. Design, Synthesis, and in Vitro Evaluation of Dibenzo[a,d]cycloheptene and Dibenzo[b,f]oxepin Derivates. Searching for Bioisosteres of Biphenyltetrazole Using a Three-Dimensional Search Technique. J. Med. Chem. 1995, 28, 2728-2741.
11. Catalyst, version 4.7 (software package); Accelrys, Inc. (previously known as Molecular Simulations, Inc.): San Diego, 2002.
12. Saladino, R.; Crestini, C.; Palamara, A. T.; Danti, M. C.; Manetti, F.; Corelli, F.; Garaci, E.; Botta, M. Synthesis, Biological Evaluation, and Pharmacophore Generation of Uracil, 4(3H)-Pyrimidone, and Uridine Derivates as Potent and Selective Inhibitors of Parainfluenza 1 (Sendai) Virus. J. Med. Chem. 2001, 44, 4554-4562.
13. Tafi, A.; Costi, R.; Botta, M.; Di Santo, R.; Corelli, F.; Massa, S.; Ciacci, A.; Manetti, F.; Artico, M. Antifungal Agents. 10. New Derivates of 1-[(Arly)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, Synthesis, Anti-Candida Activity, and Quantitative Structure-Analysis Relationship Studies. J. Med. Chem. 2002, 45, 2720-2732.
14. Singh, J.; van Vlijmen, H.; Liao, Y.; Lee, W.; Cornebise, M.; Harris, M.; Shu, I.; Gill, A.; Cuervo, J. H.; Abraham, W. M.; Adams, S. P. Identification of Potent and Novel α4β1 Antagonists Using in Silico Screening. J. Med. Chem. 2002, 45, 2988-2993.
15. Palomer, A.; Cabre, F.; Pascual, J.; Campos, J.; Trujillo, M. A.; Entrena, A.; Gallo, M. A.; Garcia, L.; Mauleon, D.; Espinosa, A. Identification of Novel Cyclooxygenase-2 Selective Inhibitors Using Pharmacophore Models. J. Med. Chem. 2002, 45, 1402-1411.
16. Ekins, S.; Kim, R. B.; Leake, B. F.; Dantzig, A. H.; Schuetz, E. G.; Lan, L.; Yasuda, K.; Shepard, R. L.; Winter, M. A.; Schuetz, J. D.; Wikel, J. H.; Wrighton, S. A. Application of Three-Dimensional Quantitative Structure-Activity Relationships of P-Glycoprotein Inhibitors and Substrates. Mol. Pharmacol. 2002, 61, 974-981.
17. 2 Receptor Antagonists. J. Med. Chem. 2001, 45, 2160-2172.
18. Flohr, S.; Kurz, M.; Kostenis, E.; Brkovich, A.; Fourier, A.; Klabunde, T. Identification of Nonpeptidic Urotensin II Receptor Antagonists by Virtual Screening Based on a Pharmacophore Model Derived from Structure-Activity Relationships and Nuclear Resonance Studies on Urotensin II. J. Med. Chem. 2002, 45, 1799-1805.
19. Kurogi, Y.; Miyata, K.; Okamura, T.; Hashimoto, K.; Tsutsumi, K.; Nasu, M.; Moriyasu, M. Discovery of Novel Mesangial Cell Proliferation Inhibitors Using a Three-Dimensional Database Searching Method. J. Med. Chem. 2001, 44, 2304-2307.
20. Chen, G. S.; Chang, C.; Kan, W. M.; Chang, C.; Wang, K. C.; Chern, J. Novel Lead Generation through Hypothetical Pharmacophore Three-Dimensional Database Searching: Discovery of Isoflavonoids as Nonsteroidal inhibitors of Rat 5α-Reductase. J. Med. Chem. 2001, 44, 3759-6763.
21. 4 Receptor Antagonists of the Quinolinyl(bridged)aryl Series. J. Med. Chem. 2000, 43, 392-400.
22. Kaminski, J. J.; Rane, D. F.; Snow, M. E.; Weber, L.; Rothofsky, M. L.; Anderson, S. D.; Lin, S. L. Identification of Novel Farnesyl Protein Transferase Inhibitors Using Three-Dimensional Database Searching Methods. J. Med. Chem. 1997, 40, 4103-4112.
23. 2-Adrenoceptores. J. Med. Chem. 2001, 44, 2118-2132.
24. Ekins, S.; Durst, G. L.; Stratford, R. E.; Thorner, D. A.; Lewis, R.; Lonarich, R. J.; Wikel, J. H. Three-Dimensional Quantitative Structure-Permeability Relationship Analysis for a Series of Inhibitors of Rhinovirus Replication. J. Chem. Inf. Comput. Sci. 2001, 41, 1578-1586.
25. 4 Receptor. J. Chem. Inf. Comput. Sci. 2002, 42, 962-967.
26. Bureau, R.; Daveu, C.; Lancelot, J.; Rault, S. Molecular Design Based on 3D-Pharmacophore. Application to 5-HT Subtypes Receptors. J. Chem. Inf. Comput. Sci. 2002, 42, 429-436.
27. Greenidge, P. A.; Weiser, J. A comparison of methods for pharmacophore generation with the catalyst software and their use for 3D-QSAR: application to a set of 4-aminopyridine thrombin inhibitors. Mini-Rev. Med. Chem. 2001, 1, 79-87.
28. +/bile acid cotransporter. J. Lipid Res. 1999, 40, 2158-2168.
29. Manetti, F.; Corelli, F.; Biava, M.; Fioavanti, R.; Porretta, G. C.; Botta, M. Building a pharmacophore model for a novel class of antitubercular compounds. Farmaco 2000, 55, 484-491.
30. Ekins, S.; Crumb, W. J.; Dustan, S.; Wikel, J. H.; Wrighton, S. A. Three-Dimensional Quantitative Structure-Activity Relationship for Inhibition of Human Ether-a-Go-Go-related Gene Potassium Channel. J. Pharmacol. Exp. Ther. 2002, 301, 427-434.
31. Debnath, A. K. Pharmacophore Mapping of a Series of 2,4-Diamino-5-Reductase. J. Med. Chem. 2002, 45, 41-53.
32. Duncia, J. V.; Chiu, A. T.; Carini, D. J.; Gregory, G. B.; Johnson, A. J.; Price, W. A.; Wells, G. J.; Wong, P. C. C.; Timmermans, P. B. W. M.; The Discovery of Potent Nonpeptide Angiotensin II Receptor Antagonists: A New Class of Potent Antihypertensives. J. Med. Chem. 1990, 33, 1312-1329.
33. Carini, D. J.; Duncia, J. V.; Johnson, A. L.; Chiu, A. T.; Price, W. A.; Wong, P. C.; Timmermans, P. B. M. W. Nonpeptide Angiotensin II Receptor Antagonists: N-[(Benzyloxy)benzyl]-imidazoles and Related Compounds as Potent Antihypertensives. J. Med. Chem. 1990, 33, 1330-1336.
34. Wong, P. C.; Price, W. A., Jr.; Chiu, A. T.; Carini, D. J.; Duncia, J. V.; Johnson, A. L.; Wexler, R. R.; Timmermans, P. B. M. W. Nonpeptide Angiotensin II Receptor Antagonists. Studies with EXP9270 and DuP 735. Hypertension 1990, 15, 823-834.
35. Sutter, J.; Güner, O.; Hoddmann, R.; Li, H.; Waldman, M. In Pharmacophore, Perception, Development and Use in Drug Design; Giiner, O. F., Ed.; International University Line: La Jolla, CA, 2000; pp 504-506.
36. Smellie, A.; Kahn, S. D.; Teig, S. L. Analysis of Conformational Coverage. 1. Validation and Estimation of Coverage. J. Chem. Inf. Comput. Sci. 1995, 35, 285-294.
37. Smellie, A.; Kahn, S. D.; Teig, S. L. Analysis of Conformational Space. 2. Applications of Conformational Models. J. Chem. Inf. Comput. Sci. 1995, 35, 295-304.
38. Smellie, A. Poling: Promoting Conformational Variation. J. Comput. Chem. 1995, 16, 171-187.
39. World Drug Index is available in the Catalyst software package, version 4.
40. Kurogi, Y.; Güner, O. F. Pharmacophore Modeling and Three-Dimensional Database Searching for Drug Design Using Catalyst. Curr. Med. Chem. 2001, 8, 1035-1055.
41. Prendergast, K. A., K.; Greenlee, W. J.; Nachbar, R. B.; Patchett, A. A.; Underwood, D. J. Derivation of a 3D pharmacophore model for the angiotensin-II site one receptor. J. Comput.-Aided Mol. Des. 1994, 8, 491-512.
42. Ellingboe, J. W.; Collini, M. D.; Quagliato, D.; Chen, J.; Antane, M.; Schmid, J.; Hartupee, D.; White, V.; Park, C. H.; Bagli, J. F.; Tanikella, T. Metabolites of the Angiotensin II Antagonist Tasosartan: The Importance of a Second Acidic Group. J. Med. Chem. 1998, 41, 4251-4260.
43. Accelrys, I. Cost analysis in HypoGen. http://www.accelrys.com/doc/life/catalyst47/help/HypoGenAlgRef.doc.html (accessed 2002).
44. Li, H.; Sutter, J.; Hoffmann, R. HypoGen: An Automated System for Generating 3D Predictive Pharmacophore Models. In Pharmacophore Perception, Development, and Use in Drug Design; International University Line: La Jolla, 2000; pp 174-189.
45. Ensemble. Prous Science Ensemble: A new database affording a unique, integrated view of drug information. http://www.prous.com (accessed 2000).
46. Li, H.; Sutter, J.; Hoffmann, R. HipHop: Pharmacophores Based on Multiple Common-Feature Alignments. In Pharmacophore Perception, Development, and Use in Drug Design; International University Line: La Jolla, 2000; pp 71-84.
47. Wexler, R. R.; Greenlee, W. J.; Irvin, J. D.; Goldberg, M. R.; Prendergast, K.; Smith, R. D.; Timmermans, P. B. M. W. M. Nonpeptide Angiotensin II Receptor Antagonists: The Next-Generation in Antihypertensive Therapy. J. Med. Chem. 1996, 39, 625-656.
48. Zanka, A.; Nishiwaki, M.; Morinaga, Y.; Inoue, T. Pilot Scale Synthesis of a Novel Nonpeptide Angiotensin II Receptor Antagonists. Org. Process Res. Dev. 1998, 1998, 230-237.
49. Salimbeni, A.; Canevotti, R.; Paleari, F.; Poma, D.; Caliari, S.; Fici, F.; Cirillo, R.; Renzetti, A. R.; Subissi, A.; Belvisi, L.; Bravi, G.; Scolastico, C.; Giachetti, A. N-3-Substituted Pyrimidones as Potent, Orally Active, AT1 Selective Angiotensin II Receptor Antagonists. J. Med. Chem. 1995, 38, 4806-4820.
50. Le Bourdonnec, B.; Meulon, E.; Yous, S.; Goossens, J.-F.; Houssin, R.; J.-P.H. Synthesis and Pharmacological Evaluation of New Pyrazolidine-3,5-dione as AT1 Angiotensin II Receptor Antagonists. J. Med. Chem. 2000, 43, 2685-2697.
51. Wolber, G.; Langer, T. In Rational Approaches to Drug Design; Höltje, H.-D., Sippl, W., Eds.; Prous Science: Barcelona, 2001, p 390-399.
52. ISIS/Draw, version 2.1; MDL Information Systems: San Diego, 1990-1996.
53. Nagao, Y.; Hirata, T.; Goto, S.; Sano, S.; Kakehi, A.; Iizuka, K.; Shiro, M. Intramolecular Nonbonded S⋯O Interaction Recognized in (Acylimino)thiadiazoline Derivates as Angiotensin II Receptor Antagonists and Related Compounds. J. Am. Chem. Soc. 1998, 120, 3104-3110.